Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis

NCT05326048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-03-29

No results posted yet for this study

Summary

The objective of APOLLO is therefore to identify biomarkers associated with the CNS involvement phenotype in early MS patients.

Conditions

Interventions

OTHER

cytof analysis

cytof analysis of biological samples of CIS patients. Genomic analysis

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-09
Primary Completion
2022-09-09
Completion
2022-09-09

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326048 on ClinicalTrials.gov